Inhibition of frowning via injections of botulinum toxin A (BTX) into the glabellar region has shown beneficial effects in the treatment of major depression. Preliminary research suggests that improvements in the affective domain are not depression-specific, but may also translate to other psychiatric disorders.
Aim:
This 16-week, single-blind, two-center randomized controlled trial investigated the influence of BTX on clinical symptoms of borderline personality disorder (BPD).
Methods:
Fifty-four patients with BPD were randomly assigned to treatment with BTX (n = 27) or a minimal acupuncture (ACU) control condition (n = 27). Clinical outcomes were followed at 2, 4, 6, 8, 12, and 16 weeks. Primary endpoint was the relative score change on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) 8 weeks after baseline relative to the control group and adjusted for treatment center. Secondary and additional outcome variables were self-rated borderline symptoms, comorbid symptoms of depression, psychological distress, and clinical global impression.
Results:
Participants showed significant improvements at the primary efficacy endpoint in both treatment groups (BTX: M = −0.39, SD = 0.39; ACU: M = −0.35, SD = 0.42), but no superior effect of the BTX condition in comparison with the control intervention was found—F(1,5323) = 0.017, p = 0.68). None of the secondary or additional outcomes yielded significant group differences. Side effects were mild and included headache, transient skin or muscle irritations, and dizziness.
Conclusion:
Evidence regarding the efficacy of BTX for BDP remains limited, and the design of adequate control conditions presents an opportunity for further research.
AckenheilMStotz-IngenlathGDietz-BauerR, et al. (1999) M.I.N.I. Mini International Neuropsychiatric Interview, German Version 5.0.0 DSM-IV. Munich: Psychiatrische Universitätsklinik München.
2.
AdelmannPKZajoncRB (1989) Facial efference and the experience of emotion. Annual Review of Psychology40(1): 249–280.
3.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (4th edn., Text Rev.). Washington, DC: American Psychiatric Association.
4.
ArmourMSmithCAWangLQ, et al. (2019) Acupuncture for depression: A systematic review and meta-analysis. Journal of Clinical Medicine8(8): 1140.
5.
BeckATSteerRABrownGK (1996) Manual for Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
6.
BlackDWZanariniMCRomineA, et al. (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry171(11): 1174–1182.
7.
BlumNSt JohnDPfohlB, et al. (2008) Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: A randomized controlled trial and 1-year follow-up. American Journal of Psychiatry165(4): 468–478.
8.
BorkovecTDNauSD (1972) Credibility of analogue therapy rationales. Journal of Behavior Therapy and Experimental Psychiatry3(4): 257–260.
9.
BozzatelloPRoccaPDe RosaML, et al. (2020) Current and emerging medications for borderline personality disorder: Is pharmacotherapy alone enough?Expert Opinion on Pharmacotherapy21(1): 47–61.
10.
BrinMFDurgamSLumA, et al. (2020) OnabotulinumtoxinA for the treatment of major depressive disorder: A phase 2 randomized, double-blind, placebo-controlled trial in adult females. International Clinical Psychopharmacology35(1): 19–28.
11.
ChaeYLeeY-SEnckP (2018) How placebo needles differ from placebo pills?Frontiers in Psychiatry9: 243.
12.
ColagiuriBSmithCA (2012) A systematic review of the effect of expectancy on treatment responses to acupuncture. Evidence-Based Complementary and Alternative Medicine2012: 857804.
13.
ColesNALarsenJTKuribayashiJ, et al. (2019) Does blocking facial feedback via botulinum toxin injections decrease depression? A critical review and meta-analysis. Emotion Review11(4): 294–309.
14.
CooperAAConklinLR (2015) Dropout from individual psychotherapy for major depression: A meta-analysis of randomized clinical trials. Clinical Psychology Review40: 57–65.
15.
DaviesSBellDIrvineF, et al. (2011) Self-administered acupuncture as an alternative to deliberate self-harm: A feasibility study. Journal of Personality Disorders25(6): 741–754.
16.
DerogatisLR (1992) SCL-90-R: Administration, Scoring and Procedures Manual-I for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series. Towson, MD: Clinical Psychometric Research.
17.
DoeringBKRiefWPetrieKJ (2014) Lessons to be learned from placebo arms in psychopharmacology trials. In: BenedettiFEnckPFrisaldiE, et al. (eds) Placebo. Berlin: Springer, pp.273–290.
18.
DoneganNHSanislowCABlumbergHP, et al. (2003) Amygdala hyperreactivity in borderline personality disorder: Implications for emotional dysregulation. Biological Psychiatry54: 1284–1293.
19.
FinziERosenthalNE (2014) Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial. Journal of Psychiatric Research52: 1–6.
20.
FinziERosenthalNE (2019) Botulinum toxin therapy of social anxiety disorder a case series. Journal of Clinical Psychopharmacology39(4): 410–412.
21.
FinziEKelsLAxelowitzJ, et al. (2018) Botulinum toxin therapy of bipolar depression: A case series. Journal of Psychiatric Research104: 55–57.
22.
FirstMBGibbonMSpitzerRL, et al. (1997) Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Association.
23.
FrankeGH (2002) Die Symptom-Checkliste Von Derogatis (SCL-90-R)—Deutsche Version—Manual (2nd edn.). Göttingen: Beltz Test.
24.
FurukawaTANomaHCaldwellDM, et al. (2014) Waiting list may be a nocebo condition in psychotherapy trials: A contribution from network meta-analysis. Acta Psychiatrica Scandinavica130(3): 181–192.
25.
GrantBFChouSPGoldsteinRB, et al. (2008) Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: Results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. The Journal of Clinical Psychiatry69(4): 533–545.
26.
GuyW (1976) Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health, pp.218–222.
27.
HennenlotterADreselCCastropF, et al. (2009) The link between facial feedback and neural activity within central circutries of emotion: New insights from botulinum toxin-induced denervation of frown muscles. Cerebral Cortex19(3): 537–542.
28.
HollifieldMSinclair-LianNWarnerTD, et al. (2007) Acupuncture for posttraumatic stress disorder: A randomized controlled pilot trial. The Journal of Nervous and Mental Disease195(6): 504–513.
29.
HoneckPWeissCSterryW, et al. (2003) Reproducibility of a four-point clinical severity score for glabellar frown lines. British Journal of Dermatology149(2): 306–310.
30.
KaptchukTJKelleyJMConboyLA, et al. (2008) Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome. BMJ336(7651): 999–1003.
31.
KarstMFinkM (2016) Acupuncture—a biomedical information therapy: A translational analysis. Medical Acupuncture28(6): 308–315.
32.
KimMJNetaMDavisFC, et al. (2014) Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: Preliminary findings from an A-B-A design. Biology of Mood & Anxiety Disorders4(1): 11.
33.
KleindienstNJungkunzMBohusM (2020) A proposed severity classification of borderline symptoms using the borderline symptom list (BSL-23). Borderline Personality Disorder and Emotion Dysregulation7: 11.
KrügerTHCMagidMWollmerMA (2016) Can botulinum toxin help patients with borderline personality disorder?The American Journal of Psychiatry173(9): 940–941.
36.
LiebKVollmBRuckerG, et al. (2010) Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry196(1): 4–12.
37.
LinLLLiH-PYangJ-W, et al. (2021) Acupuncture for psychological disorders caused by chronic pain: A review and future directions. Frontiers Neuroscience14: 626497.
38.
LittleRJARubinDB (2002) Statistical Analysis with Missing Data (2nd edn.). Hoboken, NJ: John Wiley & Sons.
39.
LundINäslundJLundebergT (2009) Minimal acupuncture is not a valid placebo control in randomised controlled trials of acupuncture: A physiologist’s perspective. Chinese Medicine4: 1.
40.
McMainSFLinksPSGnamWH, et al. (2009) A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry166(12): 1365–1374.
41.
MagidMFinziEKrügerTHC, et al. (2015) Treating depression with botulinum toxin: A pooled analysis of randomized controlled trials. Pharmacopsychiatry25(06): 205–210.
42.
MagidMReichenbergJSPothPE, et al. (2014) Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry75(8): 837–844.
43.
MakuntsTWollmerMAAbagyanR (2020) Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Scientific Reports10: 12851.
44.
MatzkeBHerpertzSCBergerC, et al. (2014) Facial reactions during emotion recognition in borderline personality disorder: A facial electromyography study. Psychopathology47: 101–110.
45.
MontgomerySAÅsbergM (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry134(4): 382–389.
46.
MusialF (2019) Acupuncture for the treatment of pain—a mega-placebo?Frontiers in Neuroscience13: 1110.
47.
OudMArntzAHermensMLM, et al. (2018) Specialized psychotherapies for adults with borderline personality disorder: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry52(10): 949–961.
48.
ParsaikAKMascarenhasSSHashmiA, et al. (2016) Role of botulinum toxin in depression. Journal of Psychiatric Practice22(2): 99–110.
49.
PilkingtonKKirkwoodGRampesH, et al. (2007) Acupuncture for anxiety and anxiety disorders—a systematic literature review. Acupuncture in Medicine25(1–2): 1–10.
50.
QianHShaoFLenahanC, et al. (2020) Efficacy and safety of botulinum toxin vs. placebo in depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Psychiatry11: 1267.
51.
SansoneRASansoneLA (2011) Gender patterns in borderline personality disorder. Innovations in Clinical Neuroscience8(5): 16–20.
52.
SchulzSCZanariniMCDetkeHC, et al. (2007) Olanzapine for the treatment of borderline personality disorder: A flexible-dose 12-week randomized double-blind placebo-controlled study. European Psychiatry22: S172.
53.
SchulzeJNeumannIMagidM, et al. (2021) Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis. Journal of Psychiatric Research135: 332–340.
54.
ShenXXiaJAdamsCE (2014) Acupuncture for schizophrenia. Cochrane Database of Systematic Reviews10: CD005475.
55.
SmithCAArmourMLeeMS, et al. (2018) Acupuncture for depression. Cochrane Database of Systematic Reviews3: CD004046.
56.
SoetemanDIVerheulRBusschbachJJV (2008) The burden of disease in personality disorders: Diagnosis-specific quality of life. Journal of Personality Disorders22(3): 259–268.
57.
SoussignanR (2004) Regulatory function of facial actions in emotion processes. In: ShohovSP (ed) Advances in Psychology Research: Volume 31. New York: Nova Science Publishers, pp.173–198.
58.
Stoffers-WinterlingJMVöllmBARückerG, et al. (2012) Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012(8): CD005652.
59.
ten HaveMVerheulRKaasenbroodA, et al. (2016) Prevalence rates of borderline personality disorder symptoms: A study based on the Netherlands Mental Health Survey and Incidence Study-2. BMC Psychiatry16: 249.
60.
ThaseME (1996) The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Psychiatric Clinics of North America19(2): 287–309.
61.
TomkoRLTrullTJWoodPK, et al. (2014) Characteristics of borderline personality disorder in a community sample: Comorbidity, treatment utilization, and general functioning. Journal of Personality Disorders28(5): 734–750.
62.
TorgersenSKringlenECramerV (2001) The prevalence of personality disorders in a community sample. Archives of General Psychiatry58(6): 590–596.
63.
WeimerKCollocaLEnckP (2015) Placebo effects in psychiatry: Mediators and moderators. The Lancet Psychiatry2(3): 246–257.
64.
WolfMLimbergerMFKleindienstN, et al. (2009) Kurzversion der borderline-symptom-liste (BSL-23): Entwicklung und überprüfung der psychometrischen eigenschaften [Short version of the borderline symptom list (BSL-23): Development and psychometric evaluation]. Psychotherapie Psychosomatik Medizinische Psychologie59(8): 321–324.
65.
WollmerMAde BoerCKalakN, et al. (2012) Facing depression with botulinum toxin: A randomized controlled trial. Journal of Psychiatric Research46(5): 574–581.
66.
World Health Organization (2004) International Statistical Classification of Diseases and Related Health Problems: Tenth Revision (2nd edn.). Geneva: World Health Organization.
67.
ZamanianAGhanbari JolfaeiAMehranG, et al. (2017) Efficacy of botox versus placebo for treatment of patients with major depression. Iranian Journal of Public Health46(7): 982–984.
68.
ZanariniMCFrankenburgFR (2008) A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders22(3): 284–290.
69.
ZanariniMCFrankenburgFRHennenJ, et al. (2004) Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry161(11): 2108–2114.
70.
ZanariniMCSchulzSCDetkeHC, et al. (2007) A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12-week randomized, double-blind, placebo-controlled study. European Psychiatry22: S172–S173.
71.
ZanariniMCStanleyBBlackDW, et al. (2010) Methodological considerations treatment trials for persons personality disorder. Annals of Clinical Psychiatry22(2): 75–83.
72.
ZanariniMCVujanovicAAParachiniEA, et al. (2003) Zanarini rating scale for borderline personality disorder (ZAN-BPD): A continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders17(3): 233–242.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
